These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 14649623

  • 1. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
    McComsey G, Maa JF.
    AIDS Read; 2003 Nov; 13(11):539-42, 559. PubMed ID: 14649623
    [Abstract] [Full Text] [Related]

  • 2. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R.
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [Abstract] [Full Text] [Related]

  • 3. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [Abstract] [Full Text] [Related]

  • 4. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M, Walker UA, Sevastianova K, Setzer B, Wågsäter D, Eriksson P, Yki-Järvinen H, Sutinen J.
    J Infect Dis; 2009 Jul 15; 200(2):252-62. PubMed ID: 19519254
    [Abstract] [Full Text] [Related]

  • 5. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E, McKinnon E, Nolan D.
    Clin Infect Dis; 2010 Sep 01; 51(5):591-9. PubMed ID: 20645860
    [Abstract] [Full Text] [Related]

  • 6. Long-term complications of antiretroviral therapy: lipoatrophy.
    Waters L, Nelson M.
    Int J Clin Pract; 2007 Jun 01; 61(6):999-1014. PubMed ID: 17504362
    [Abstract] [Full Text] [Related]

  • 7. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, Deleuze J, Morini JP, Gorin I, Calvez V, Dupin N.
    J Clin Virol; 2005 May 01; 33(1):60-4. PubMed ID: 15797366
    [Abstract] [Full Text] [Related]

  • 8. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L, Puthanakit T, Taejaroenkul S, Sirisanthana T, Sirisanthana V.
    Pediatr Infect Dis J; 2012 Apr 01; 31(4):384-8. PubMed ID: 22124211
    [Abstract] [Full Text] [Related]

  • 9. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
    Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodriguez J, Vázquez G.
    Antivir Ther; 2003 Jun 01; 8(3):223-31. PubMed ID: 12924539
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar 01; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 11. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE, Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team.
    Clin Infect Dis; 2004 Jan 15; 38(2):263-70. PubMed ID: 14699460
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
    Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwolé-Sida M, Delaporte E, Bork K, Laurent C.
    Antivir Ther; 2010 Jan 15; 15(7):1039-43. PubMed ID: 21041920
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E, Tinelli C, Minoli L, Sacchi P, Filice G, Zocchetti C, Meneghetti G, Bruno R, Maserati R.
    Antivir Ther; 2002 Sep 15; 7(3):175-80. PubMed ID: 12487384
    [Abstract] [Full Text] [Related]

  • 18. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan 15; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 19. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G, Toro GM.
    BMC Infect Dis; 2005 Oct 03; 5():80. PubMed ID: 16202141
    [Abstract] [Full Text] [Related]

  • 20. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T.
    Trans R Soc Trop Med Hyg; 2010 Feb 03; 104(2):148-53. PubMed ID: 19732926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.